299 related articles for article (PubMed ID: 25051299)
1. Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients.
Dobes P; Podhorec J; Coufal O; Jureckova A; Petrakova K; Vojtesek B; Hrstka R
Oncol Rep; 2014 Oct; 32(4):1695-702. PubMed ID: 25051299
[TBL] [Abstract][Full Text] [Related]
2. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
Glück S; Ross JS; Royce M; McKenna EF; Perou CM; Avisar E; Wu L
Breast Cancer Res Treat; 2012 Apr; 132(3):781-91. PubMed ID: 21373875
[TBL] [Abstract][Full Text] [Related]
3. Preliminary monocentric results of biological characteristics of pregnancy associated breast cancer.
Michieletto S; Saibene T; Evangelista L; Barbazza F; Grigoletto R; Rossi G; Ghiotto C; Bozza F
Breast; 2014 Feb; 23(1):19-25. PubMed ID: 24189101
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
5. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
[TBL] [Abstract][Full Text] [Related]
6. Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer.
Uji K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
Cancer Lett; 2014 Jan; 342(1):19-26. PubMed ID: 23973262
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
8. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
9. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
10. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
11. Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer.
Noori SF; Gangi A; Nelson ME; Choi M; Mirzadehgan P; Bonk AK; Mirocha J; Amersi F; Giuliano AE
Ann Surg Oncol; 2014 Oct; 21(10):3324-9. PubMed ID: 25047471
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
[TBL] [Abstract][Full Text] [Related]
13. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.
Fernández-Cuesta L; Oakman C; Falagan-Lotsch P; Smoth KS; Quinaux E; Buyse M; Dolci MS; Azambuja ED; Hainaut P; Dell'orto P; Larsimont D; Francis PA; Crown J; Piccart-Gebhart M; Viale G; Leo AD; Olivier M
Breast Cancer Res; 2012 May; 14(3):R70. PubMed ID: 22551440
[TBL] [Abstract][Full Text] [Related]
15. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
16. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
18. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
19. A gene expression signature identifies two prognostic subgroups of basal breast cancer.
Sabatier R; Finetti P; Cervera N; Lambaudie E; Esterni B; Mamessier E; Tallet A; Chabannon C; Extra JM; Jacquemier J; Viens P; Birnbaum D; Bertucci F
Breast Cancer Res Treat; 2011 Apr; 126(2):407-20. PubMed ID: 20490655
[TBL] [Abstract][Full Text] [Related]
20. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
